Related Experiment Video

Updated: Feb 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Hepatitis C virus infection in patients with end-stage renal disease

John Wigneswaran1, David Van Wyck2, David Pegues3

  • 1DaVita Rx, Inc., Coppell, Texas, USA.

Hemodialysis International. International Symposium on Home Hemodialysis
|August 25, 2018
PubMed

Insights

New direct-acting antiviral therapies offer a cure for chronic hepatitis C virus (HCV) infection, even in patients with end-stage renal disease (ESRD). These treatments provide a safe and effective option for HCV patients with kidney complications.

Area of Science:

  • Hepatology
  • Nephrology
  • Virology

Background:

  • Chronic hepatitis C virus (HCV) infection is a significant global health issue with serious complications, including kidney impairment.
  • Patients with end-stage renal disease (ESRD) undergoing hemodialysis face a heightened risk of HCV infection due to transmission routes.
  • Previous HCV treatments for ESRD patients were limited by side effects and low efficacy.

Purpose of the Study:

  • To review the biology and pathophysiology of HCV infection.
  • To summarize current direct-acting antiviral (DAA) therapies for HCV.
  • To focus on the application and efficacy of new DAA therapies in patients with chronic kidney disease (CKD) and ESRD.

Main Methods:

  • Literature review of HCV infection, pathophysiology, and treatment options.
  • Analysis of recent studies on direct-acting antiviral (DAA) therapies.
  • Focus on data pertaining to HCV treatment in patients with renal impairment.

Main Results:

  • Direct-acting antiviral (DAA) therapies have revolutionized HCV treatment, achieving high cure rates.
  • New DAA regimens demonstrate a favorable safety profile with low pill burden and minimal side effects.
  • These advanced therapies are effective in the majority of patients, including those with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

Conclusions:

  • Modern direct-acting antiviral (DAA) therapies represent a breakthrough in managing chronic hepatitis C virus (HCV) infection.
  • HCV treatment is now highly effective and well-tolerated in patients with kidney disease, including those on hemodialysis.
  • Virological cure is achievable for most HCV-infected patients, irrespective of their renal status, with new DAA regimens.

Keywords:
Hepatitis Cdirect-acting antiviralend-stage renal disease

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K

Related Concept Videos

Stages of Infection01:26

Stages of Infection

Stages of infection describe what happens to a susceptible host once a pathogen invades the human body. The stages of infection are incubation, prodromal, illness, stage of decline, and convalescence. The incubation stage is the period from exposure to a pathogen until symptoms start. The infected person is unaware of impending illness as the pathogens grow and multiply within the body. The duration may vary depending on the type of infection. The incubation period of measles averages ten to...
65.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
202
What are Viruses?00:50

What are Viruses?

Overview
128.3K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234